Academic International Journal of Medical Update
ISSN: 2984-7761
Aca. Intl. J. Med. U. 2024; 2(2) 35-43
Journal homepage: www.aipublishers.org/aijmu

The Role of Genetics in Neurological Disorders: From Rare Diseases to Common Conditions

Nuha Majeed Farhan[1], Lubab Mohammed Awad[2], Intisar Masier Abd[3]

[1]Department of Pathological Analysis, College of Applied Sciences, University of Fallujah, Iraq
nuhaa.majeed.ext@uofallujah.edu.iq
[2]General Directorate of Anbar Education, Ministry of Education, Iraq
lubabmo373@gmail.com
[3]General Directorate of Anbar Education, Ministry of Education, Iraq
intesarmasier@gmail.com

Article Info.
Article history:
Received 2 August 2024
Revised 1 September 2024
Published 16 October 2024
Keywords:
neurological disorders, Genetic mutations, multifactorial conditions, Antisense oligonucleotides (ASOs), CRISPR-Cas9 gene editing.
How to cite:
Nuha Majeed Farhan, Lubab Mohammed Awad, Intisar Masier Abd, The Role of Genetics in Neurological Disorders: From Rare Diseases to Common Conditions, *Aca. Intl. J. Med. U. 2024; 2(2) 35-43*
DOI:
https://doi.org/10.59675/U226

Abstract

Neurological disorders result from neurological diseases affecting the brain, spinal cord, and peripheral nerves and include rare genetic diseases like Huntington's disease and spinal muscular atrophy, as well as common diseases such as Alzheimer's, Parkinson's disease, and epilepsy. These conditions are strongly influenced by genetics, and genetics contribute to the onset, the progression of the disease, the severity of symptoms, and treatment responsiveness. Genetics is relevant not only to inheritance but also to de novo mutations, polygenic risk factors, and gene-environment interactions that contribute to the clinical phenotype of these disorders.

Although the many mutations and heredity patterns of neurological conditions have not been worked out completely, genetic research has come a long way to help us learn more about these conditions. Single gene mutations are invaluable, particularly for rare disorders, for early diagnosis and targeted interventions. For instance, predictive gene testing, such as checking for the HTT gene mutation linked to Huntington's disease, allows people to learn if they are at risk of the disease early on — before their symptoms develop.

On the other hand, most common neurological disorders involve genetic landscapes much more complicated, with small increases in risk due to more than one gene. Since epigenetic factors and certain environmental factors can further influence these risks, prevention is always in order. For example, people with APOE ε4 allele are more likely to develop Alzheimer’s disease, but lifestyle factors such as diet and exercise may reduce this risk. Such complexity emphasizes the necessity for complete studies,

including genome-wide association studies (GWAS), epigenetics, and transcriptomics, to define the molecular mechanisms of these multifactorial disorders.

Genetic testing has recently become one of the most critical tools in neurology, allowing us to make early diagnoses with great precision and to offer a comprehensive and personalized treatment plan based on patient's genetic profiles. For instance, these genetic mutations can help physicians choose the best medicines for patients with epilepsy. Gene-based therapies, including gene replacement, antisense oligonucleotides (ASOs), and gene editing (e.g., CRISPR-Cas9), are emerging as potential treatments for human disease and as a therapeutic for spinal muscular atrophy and Duchenne muscular dystrophy. Indeed, as these therapies become more common, these must be addressed as ethical concerns, such as genetic privacy issues, risk of genetic discrimination, and unintended consequences of gene manipulation.

This review focuses on giving a brief but detailed account of the genetic components of neurological disorders, ranging from rare monogenic diseases to common multifactorial disorders. It describes key genetic discoveries and discusses developing genetic diagnostic and therapeutic strategies and the ethical implications of these developments. The integration of genetic insights directly into clinical practice has the potential to provide a personal roadmap that could lead to individualizing the diagnostic, treatment, and prevention approaches for neurological disorders and enhance patient outcomes.

1. Introduction

Recent genetic research has uncovered molecular underpinnings of neurological disorders, contributing to how neurological disorders arise and how they may lead to new therapies. With advancing genomics, we know what genetic mutations (such as single nucleotide polymorphisms or SNPs, copy number variations (CNVs)), or abnormal gene sharing and inheritance patterns, are implicated in developing neurological conditions. Numerous disorders result from clearly defined genetic mutations; specific gene mutations directly cause Huntington's disease and spinal muscular atrophy. However, these monogenic disorders frequently present with clear patterns of inheritance, thereby enabling the prediction of the risk of disease onset in families. [1]

In other cases, neurological disorders become polygenic or multifactorial due to the interaction between numerous genes and numerous environmental factors. For example, genetic risk factors, such as the APOE ε4 allele, for Alzheimer's combine with lifestyle, exposure to toxins, and age as non-genetic contributors to Alzheimer's and Parkinson's disease. These factors play in turns quite strongly and can decisively alter disease onset, progression, and severity.

Understanding genetic contributions helps discover biomarkers for early diagnosis and prognosis in overlapping clinical phenotype disorders. Genetic testing can tell you if you have a particular condition or not and how to best treat it based on that person's genetic profile. In addition, genetic research has been integrated into neurology, widening therapeutic horizons from targeted drugs to gene therapies aimed at correcting the underlying genetic abnormality. As genetic research advances, genetic diagnosis, management, and prevention of neurological disorders continue progressing, and you can expect more effective and personalized care. [2]

Aca. Intl. J. Med. U. 2024; 2(2)35-43: https://doi.org/10.59675/U226

2. Genetic Contribution to Rare Neurological Disorders

Otherwise, one or more specific genetic mutations are the leading cause of infrequent neurological disorders, also known as orphan diseases. Although these disorders are individually rare, taken together, they affect a significant number of people, often with severe and debilitating symptoms. Rare neurological disorders have a vital genetic component, offering clear molecular clues as to what causes them and thus are essential targets for genetic research. [2]

A well-known example is Huntington's disease, a neurodegenerative disease with a mutation in the HTT gene, developing into an expanded CAG trinucleotide repeat. The defect in creating this genetic disease results in abnormal dysfunction of huntingtin protein products that then cause progressive motor disturbances, cognitive decline, and psychiatric symptoms. Huntington's disease is a perfect example of a monogenic neurological disorder, with the mutation and disease completely unrelated and directly associated. [3]

Amyotrophic lateral sclerosis (ALS) is another rare disease in which motor neurons degenerate. Although most cases are idiopathic, about 10 per cent are familial and related to gene mutations, including SOD1, C9orf72, and TARDBP. There isn't a single genetic form of ALS, but these variants are good models for the illness because they share disease mechanisms and may be amenable to treatment.

Other genetic mutations, such as those found with muscular dystrophies like Duchenne muscular dystrophy (DMD), cause different types of muscular dystrophy. It causes a muscle integrity breakdown due to a deficiency in dystrophin, a protein crucial for dystrophin, so muscle weakness progresses to cardiac complications. [4]

Because these neurological disorders are strongly linked to genes, genetic testing can be used to diagnose them, find carriers, and as a basis for gene-based therapies like gene replacement and antisense oligonucleotides, which aim to fix or compensate for genetic flaws.



Figure 1: *Prevalence of Neurological Disorders*

Aca. Intl. J. Med. U. 2024; 2(2)35-43: https://doi.org/10.59675/U226

Table 1: *Examples of Rare Neurological Disorders with Known Genetic Mutations*

Disorder	Gene(s) Involved	Inheritance Pattern	Key Symptoms
Huntington's Disease	HTT	Autosomal Dominant	Motor dysfunction, cognitive decline
Amyotrophic Lateral Sclerosis (ALS)	SOD1, C9orf72	Autosomal Dominant or Sporadic	Muscle weakness, respiratory difficulties
Spinal Muscular Atrophy	SMN1	Autosomal Recessive	Muscle wasting, mobility issues
Duchenne Muscular Dystrophy	DMD	X-linked Recessive	Muscle degeneration, cardiac complications

2.1 Huntington's Disease

Huntington's disease (HD) is a progressive, degenerative neurological disorder of the brain featuring the delayed onset of initially subtle progressive motor, cognitive, and psychiatric dysfunction. A mutation in the HTT gene located on chromosome 4, resulting in the abnormal CAG trinucleotide repeat expansion, causes it. The repeat expansion produces a mutant huntingtin protein that accumulates in neurons, leading to cell dysfunction and death, particularly in regions of the brain (movement and cognition). [2]

The quantity of CAG repeats in the HTT gene will determine the onset and severity of the disease. Anyone with 40 or more repeats will develop HD; the more repeats you have, the earlier you develop HD. Late-onset or incomplete penetrance may happen at intermediate repeat lengths (36–39 repeats). Shorter repeat lengths (26–35 repeats) are thought not to put people at risk for the disease, but because anticipation is a part of the disease, repeat length that grows in future generations may be expected when passed down from the father.

Genetic testing of the HTT mutation makes predictive diagnosis of Huntington's disease in asymptomatic individuals with a family history of Huntington's disease possible. This testing not only tells us that the mutation is present but also tells us the likelihood of onset based on the CAG repeat length. Genetic counselling for emotional, psychological, and ethical issues is provided concurrently with such predictive testing, as there is no cure for the disease.

There are no treatments for HD yet, but genetic research has led to several ideas that aim to lower hunting, protein production, or aggregation. These ideas are being tested in ongoing clinical trials of gene-silencing approaches and others.

2.2 Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a hereditary disease in which the disease-induced loss of motor nerve cells in the spinal cord and muscle atrophy leads to weakness. The most frequent cause is insufficient production of the survival motor neuron (SMN) protein due to mutations in the SMN1 (survival motor neuron 1) gene. This protein depends on the maintenance of motor neurons, which, if deficient, degenerates motor neurons, resulting in the hallmark symptoms of SMA, including difficulty breathing, moving, and swallowing.

SMA severity varies and is based on multiple types, where the type is classified as the age at onset and the highest motor function accomplished. SMA type 1 appears in infancy and, if untreated, leads to early mortality. They cause considerable physical disability but have a later onset and are less severe forms, such as types 2 and 3. [4]

Recent advances in genetics have made new drug development possible. For example, gene therapy is based on onasemnogene abeparvovec (Zolgensma), an oncolytic viral vector that transduces the SMN1 gene to motor neurons with a functional copy of the SMN1 gene. In affected infants, this one-time intravenous infusion restores SMN protein production, substantially improving their motor function and survival.

Other available therapies are nusinersen (Spinraza), an antisense oligonucleotide that enhances the synthesis of SMN protein from the SMN2 gene, a backup gene that can partially compensate for the lack of SMN1. However, these treatments have completely changed the prognosis for patients with SMA, turning their view of prognosis from symptomatic management to disease-modifying therapy that improves quality of life.

3. Genetics of Common Neurological Disorders

Alzheimer's disease, Parkinson's disease, and epilepsy are all common neurological disorders that are affected by, but not fully explained by complex genetic and environmental factors; this means that their causes are not as simple as those of rare monogenic diseases. The genetics of these conditions are typically multifactorial, involving multiple genes acting together with their environment (lifestyle, diet, and environmental exposures) to affect disease onset and progression. [2]

While the presence of specific genetic variants, like the APOE ε4 allele, dramatically increases a person's risk of Alzheimer's disease, it doesn't necessarily determine or prevent it. Other genetic variations and factors, such as genes involved in processing amyloid precursor protein (APP) and tau, also make people more likely to get the disease. Finally, environmental and lifestyle factors (physical activity, diet) can further modulate genetic risk to modify the age of onset and progression of symptoms.

Like Parkinson's disease, the genetic architecture for alcoholism is also multifactorial; many genes affect risk, including LRRK2, SNCA, PARK7, etc. These genes can affect processes including protein aggregation, mitochondrial dysfunction, and oxidative stress and are characteristic of a neurodegenerative disease. Genetic factors, such as non-genetic factors such as pesticide exposure and head injury, are essential.

Epilepsy and recurrent seizures have a complex polygenic influence, with some forms genetically caused by single gene mutations and others from complex polygenic influence. For instance, mutations in ion channel genes such as SCN1A can cause specific epilepsy syndromes, but other kinds of epilepsy arise in which genetic and environmental factors reduce the seizure threshold. [5]

Knowing this genetic complexity permits the refinement of diagnostic criteria, the development of targeted therapies, and the identification of individuals at higher risk for common neurological disorders to guide their management.

Table 2: *Genetic Factors Associated with Common Neurological Disorders*

Disorder	Genetic Risk Factors	Pathophysiological Mechanism
Alzheimer's Disease	APOE ε4, APP, PSEN1, PSEN2	Amyloid plaque formation, tau protein dysfunction
Parkinson's Disease	SNCA, LRRK2, GBA	Dopaminergic neuron degeneration
Epilepsy	SCN1A, GABRA1, CHRNA4	Abnormal neuronal excitability

3.1 Alzheimer’s Disease

Alzheimer's disease (AD) is a neurodegenerative disorder involving progressive memory loss and cognitive decline, as well as behaviour change. From a histopathological perspective, it is characterized by amyloid beta (A β) plaques and neurofibrillary tangles of abnormally phosphorylated tau protein in the brain. However, pathological changes described here occur in the degeneration of neurons and synapses, first in the hippocampus and later in other cortical areas and are the hallmarks of Alzheimer's. [1]

The APOE ε4 allele (the apolipoprotein E gene variant) is a significant genetic risk factor for late-onset Alzheimer's. Those who have one copy of the APOE ε4 variant have a greater likelihood of developing Alzheimer's than those carrying the more common APOE ε3 variation, and there is a further increased likelihood of developing Alzheimer's if they are holding two copies of the APOE ε4 variant. An association has been found between the APOE ε4 allele and earlier onset and faster progression of the disease. It is not deterministic, especially for people with a familial AD history. Therefore, both genetic predisposition and family history must influence disease development.

In rare, early-onset familial forms of Alzheimer's disease, other genes, such as those in APP processing, PSEN1, and PSEN2 genes, are associated. These mutations cause amyloid-beta to be produced or mis cleared in excess, leading to early neurodegenerative changes.

Information about genetic risk factors such as APOE ε4 helps refine a risk assessment, earlier diagnosis, and further improvement of therapies aiming to modify amyloid and tau pathology. In addition, current research is investigating those lifestyle and environmental factors that might interact with genetic risk to develop strategies for delaying or possibly preventing the onset of Alzheimer's disease.

3.2 Parkinson's Disease

Parkinson's disease (PD) is a progressive, neurodegenerative disorder with widespread tremors, bradykinesia, rigidity, and postural instability resulting from the loss of dopaminergic neurons of the substantia nigra of the brain. The majority of people with Parkinson's have what's called sporadic Parkinson's, which means that they don't know just what caused it. Still, about 10 per cent have a genetic form of the disease that gives researchers a hint of how it operates. [2]

Among the critical genetic discoveries in Parkinson's are those involving mutations of genes, including SNCA for the alpha-synuclein protein and LRRK2 (leucine-rich repeat kinase 2). A mutation in SNCA can cause overproduction or improper folding of alpha-synuclein, which then clumps together to form Lewy bodies, the pathologic hallmark of Parkinson's. These protein aggregates interfere with the cell, causing known cellular dysfunction and contributing to neuronal death. The most common genetic cause of familial Parkinson's and a contributor to sporadic cases is LRRK2 mutation. The cellular processes that LRRK2 mutations affect are protein degradation, mitochondrial function, and inflammatory responses, all of which have essential roles in neurodegeneration. [6]

In addition to PARK7 (DJ-1), PINK1, and PRKN (parkin) genes have also been implicated in Parkinson's, especially in early-onset cases of the disease. These genes function to maintain mitochondria and protect against oxidative stress, making mitochondrial dysfunction a key factor in the pathogenesis of Parkinson's disease.

Identifying these genetic mutations not only revealed clues into Parkinson's disease's mechanism but also provided targets for disease-targeting approaches. However, much current research aims to develop therapies that affect only specific genetic defects, such as small molecules, gene therapies for LRRK2 mutations, or agents that block alpha-synuclein aggregation. This personalized approach promises to change the disease course and improve patient outcomes. [10]

4. Genetic Diagnostics in Neurology

In recent years, genetic testing has emerged as a critical tool for diagnosing neurological disorders, primarily when the causative genes are known. Typically, however, the diagnostic process begins with sorting out a patient's family history to determine what, if anything, can be pinpointed regarding possible genetic links to neurological conditions. The inheritance patterns of symptoms, such as early onset neurodegenerative disease or recurrent seizures, can help define the genetic testing strategies. [7]

Based on a family history assessment, A clinical examination is conducted to find key symptoms of genetic disorders. It narrows down a range of possible genetic conditions as the cause and the methods of selecting appropriate testing.

Genetic techniques can be applied in different ways. Whole-exome sequencing (WES) is helpful when a condition has many genetic causes because it can identify mutations across the entire genome. Targeted gene panels (panels of specific genes) are used for diseases with known genetic syndromes, like familial epilepsy or muscular dystrophies. Down syndrome chromosomal abnormalities are detected by karyotyping.

The role of result interpretation and genetic counselling in turning testing results into clinical practice once testing is completed is vital. Genetic counsellors suggest taking a test based on the test outcome and their implications on the patient and family members, such as the risk prediction of the asymptomatic individual. [6]

Genetic testing helps determine diagnoses in symptomatic patients and provides information for personalized therapeutic approaches. For example, pharmacogenomics directs drug selection for the individual based on his genetic makeup, choosing medication that is more effective and has fewer side effects. Genetic diagnostics in neurology is a major glue in the development of precision medicine. It provides a more accurate diagnosis, estimates a greater risk of disease, and can lead to optimal treatment strategies.

5. Therapeutic Implications of Genetic Findings

The discovery of genetic factors involved in neurological disorders has fueled efforts to develop new treatments directed at the underlying mechanisms of neurological disease. Gene therapy, antisense oligonucleotides (ASOs), and CRISPR-Cas9 gene editing are all gene therapy strategies with their mechanism of action for relating to genetic abnormalities. [7]

5.1 Gene Therapy

Gene therapy attempts to replace or repair a defective gene to restore normal function. Kaphammer noted a critical example of progress in this field: the approval of onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy (SMA), which delivers a functional copy of the SMN1 gene to affected motor neurons. Gene therapy can significantly improve motor function and survival in infants with SMA after a single infusion, making this a transformative moment for the disease.

5.2 Antisense Oligonucleotide (ASO)

Synthetic strands of nucleotides known as ASOs are synthetic deformable RNA designed to bind to a specific mRNA sequence and then modulate gene expression. They have proved promising at treating neurological conditions like Huntington's disease and amyotrophic lateral sclerosis (ALS). ASO nusinersen (Spinraza) is just one example where the ASO is increasing the production of a protein from the SMN2 gene and, therefore, individual outcomes. ASOs are being studied in Huntington's disease to reduce the production of mutant huntingtin protein, making the disease slower.

5.3 CRISPR-Cas9 Gene Editing

An advantage of direct genome editing using the technology known as CRISPR-Cas9 is that it can be used to correct mutations linked to neurological disorders. This approach is part of a pursuit of genome editing for conditions like Duchenne muscular dystrophy, where it could return the dystrophin gene to produce its function. CRISPR Cas9 is still in experimental stages and could be a valuable tool for therapeutically addressing the genetic basis of neurological diseases that potentially have lasting effects. [8]

Advances in genetic research are changing the way we view these approaches, moving the paradigm from symptom management to targeted disease modification and providing new hope for genetic neurological conditions, which to date have been beyond treatment.

6. Ethical Considerations in Genetic Testing and Therapy.

Integrating gene-based genetic testing and therapeutics into clinical neurology brings a host of ethical considerations that need to be carefully addressed. Storing and collecting genetic information that is inherently sensitive creates privacy concerns. Legal protections like the Genetic Information Nondiscrimination Act can protect your genetic information, but are at risk that this information be accessed without your consent and subject to genetic discrimination by employers or insurance companies. [5]

The psychological impact of predictive genetic testing, especially in asymptomatic patients, could be significant. Anxiety is known to occur, and life planning is altered when someone knows they carry a genetic mutation to a neurological disorder such as Huntington's disease. As a result, great care should be taken when choosing to undergo genetic testing, with thorough genetic counselling taking place simultaneously.

Genetic testing and gene therapy are based on a fundamental informed consent requirement. Patients must be fully informed of these procedures' risks, benefits, and uncertainties. With gene therapies, the potential for unintended off-target effects or longer-term consequences means these are still high-risk therapies for patients and raise questions about safety and the ethics of their use in children or for life-threatening conditions.

Resolving the ethical issues through the creation of robust policy and the expanded provision of genetic counselling can maximize genetic progress and minimize potential harm.

7. Conclusion

Genetic research has increased exponentially in terms of our understanding of neurological disorders, from rare single-gene disorders to complex conditions with multiple genetic and environmental factors. Genetic mutations and how they work have been identified, and their biological impact improved diagnostic accuracy, also opening the door for the use of approaches such as gene therapy, antisense oligonucleotides, and genome editing technology, such as CRISPR Cas9. [8]

This significant transition from the medicine of symptom management to personalized medicine depending on genetic profiles is natural for neurology: earlier diagnosis, more tailored therapeutic options, and even disease modification. However, as genetic testing and gene-based therapies become more widespread, they cannot address ethical challenges, such as privacy, genetic discrimination, and informed consent.

However, there are tremendous benefits to be gleaned from genetic research in neurology and a future that, with genetic information, promises more personalized treatment, better patient outcomes, and more significant contributions to the neurology field. The integration of genetics into clinical practice is underway and will revolutionize the management of neurological disorders, bringing precision medicine into reality. [9]

References

1. Guerreiro R BJ. The age factor in Alzheimer’s disease: where does it fit in? In.: Nat Rev Neurol; 2015. p. 11(2):108-18.
2. Ross CA AEWEea. Huntington disease: natural history, biomarkers and prospects for therapeutics. In.: Nat Rev Neurol.; 2014. p. 10(4):204-16.
3. Verhaart IE RAWIea. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. In.: Orphanet J Rare Dis.; 2017. p. 12(1):124.
4. Rowland LP SN. Amyotrophic lateral sclerosis. In.: N Engl J Med; 2001. p. 344(22):1688-1700.
5. Athanasiadis AP KPMAea. Clinical utility of exome sequencing in neurology. In.: Mol Genet Genomic Med.; 2019. p. 7(10).
6. Naylor PE LCSS. Genome editing for neurological disorders. In.: J Neurosci Res; 2020. p. 98(6):1161-68.
7. Landau SM HAJW. Memory decline accompanies subclinical amyloid accumulation. In.: Neurology; 2018. p. 90(17).
8. Hildebrandt T WD. CRISPR/Cas9 in the clinical treatment of neurodegenerative diseases. In.: Neurogenetics; 2019. p. 20(2):103-10.
9. Miller TM PADWea. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. In.: Lancet Neurol; 2013. p. 12(5):435-42.
10. Schneider SA AR. Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson's disease. In.: J Neurol.; 2020. p. 267(3):860-69.